Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q3 2012 · 10-Q
Revenue$128.12M$128.12M+13.0% vs Q3 2011 Net Income-$5.36M-$5.36MN/M vs Q3 2011 EPS Diluted-$0.04-$0.04N/M vs Q3 2011 Operating Income-$10,491,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$799,000N/M Margins · derivedOperating margin-8.2%+5.5 pt vs Q3 2011
Net margin-4.2%+11.4 pt vs Q3 2011
ended Sep 30, 2012 · filed Oct 29, 2012 · 29 d after period end